{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:13:42Z","timestamp":1773389622408,"version":"3.50.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"\n Background<\/jats:title>\n \n Vasculitis associated with myeloproliferative neoplasms is rare, and reports on its treatment are limited. Herein, we report a case of\n Janus Kinase2 (JAK2)<\/jats:italic>\n V617F mutation\u2013positive essential thrombocythemia (ET) associated with vasculitis.\n <\/jats:p>\n <\/jats:sec>\n \n Case presentation<\/jats:title>\n \n A 60-year-old man with\n JAK2<\/jats:italic>\n V617F mutation\u2013positive ET underwent coronary artery bypass grafting after recurrent myocardial infarctions and coronary stent occlusions. Intraoperative and pathological findings led to a diagnosis of vasculitis. Treatment with hydroxycarbamide and ruxolitinib resulted in decreased platelet counts and improved vasculitis, with no subsequent recurrence of cardiovascular events.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n This rare case shows that ruxolitinib can be effective in treating vasculitis complications in patients with\n JAK2<\/jats:italic>\n mutation\u2013positive ET.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1781998","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T05:26:05Z","timestamp":1773379565000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Ruxolitinib reverses systemic vasculitis driven by JAK2 V617F\u2013mutated essential thrombocythemia: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Yutaro","family":"Ashida","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Hematology, and Clinical Immunology, Hirosaki University Graduate School of Medicine","place":["Hirosaki, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Ota","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hematology, and Clinical Immunology, Hirosaki University Graduate School of Medicine","place":["Hirosaki, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nao","family":"Ishidoya","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hematology, and Clinical Immunology, Hirosaki University Graduate School of Medicine","place":["Hirosaki, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhisa","family":"Murai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hematology, and Clinical Immunology, Hirosaki University Graduate School of Medicine","place":["Hirosaki, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Amenomori","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hematology, and Clinical Immunology, Hirosaki University Graduate School of Medicine","place":["Hirosaki, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Hasui","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hematology, and Clinical Immunology, Hirosaki University Graduate School of Medicine","place":["Hirosaki, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Department of Vascular and Inflammatory Medicine, Hirosaki University Graduate School of Medicine","place":["Hirosaki, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hematology, and Clinical Immunology, Hirosaki University Graduate School of Medicine","place":["Hirosaki, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroto","family":"Hiraga","sequence":"additional","affiliation":[{"name":"Department of Bioscience and Laboratory Medicine, Hirosaki University Graduate School of Health Sciences","place":["Hirosaki, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Kamata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hematology, and Clinical Immunology, Hirosaki University Graduate School of Medicine","place":["Hirosaki, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Ichikawa","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Nephrology, Hirosaki University Graduate School of Medicine","place":["Hirosaki, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Nephrology, Hirosaki University Graduate School of Medicine","place":["Hirosaki, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaiqiang","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Thoracic and Cardiovascular Surgery, Hirosaki University Graduate School of Medicine","place":["Hirosaki, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahito","family":"Minakawa","sequence":"additional","affiliation":[{"name":"Department of Thoracic and Cardiovascular Surgery, Hirosaki University Graduate School of Medicine","place":["Hirosaki, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotake","family":"Sakuraba","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hematology, and Clinical Immunology, Hirosaki University Graduate School of Medicine","place":["Hirosaki, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017578","article-title":"Genetic basis and molecular profiling in myeloproliferative neoplasms","volume":"141","author":"Luque Paz","year":"2023","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41392-024-01934-w","article-title":"The JAK-STAT pathway: from structural biology to cytokine engineering","volume":"9","author":"Lv","year":"2024","journal-title":"Sig Transduct Target Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1254868","article-title":"Philadelphia chromosome-negative myeloproliferative chronic neoplasms: is clonal hematopoiesis the main determinant of autoimmune and cardio-vascular manifestations","volume":"10","author":"Fulvio","year":"2023","journal-title":"Front Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab337","article-title":"Myeloproliferative neoplasms and clonal haematopoiesis in patients with giant cell arteritis: a case\u2013control and exploratory study","volume":"61","author":"Papo","year":"2022","journal-title":"Rheumatology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s11926-022-01083-5","article-title":"Spectrum of large- and medium-vessel vasculitis in adults: neoplastic, infectious, drug-induced, autoinflammatory, and primary immunodeficiency diseases","volume":"24","author":"L\u00f6tscher","year":"2022","journal-title":"Curr Rheumatol Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.281","article-title":"Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies","volume":"2","author":"Passamonti","year":"2011","journal-title":"Oncotarget"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3390\/diagnostics12051077","article-title":"Impact of anti-endothelial cell antibodies (AECAs) in patients with polycythemia vera and thrombosis","volume":"12","author":"Cacciola","year":"2022","journal-title":"Diagnostics"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1200419109","article-title":"Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis","volume":"109","author":"Demers","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224933","article-title":"Clonal haematopoiesis across the age spectrum of vasculitis patients with Takayasu\u2019s arteritis, ANCA-associated vasculitis and giant cell arteritis","volume":"83","author":"Gutierrez-Rodrigues","year":"2024","journal-title":"Ann Rheumatic Diseases"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010588","article-title":"JAK2V617F mutation is highly prevalent in patients with ischemic stroke: a case-control study","volume":"7","author":"Kristiansen","year":"2023","journal-title":"Blood Adv"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011445","article-title":"Multiomic profiling of human clonal hematopoiesis reveals genotype and cell-specific inflammatory pathway activation","volume":"8","author":"Heimlich","year":"2024","journal-title":"Blood Advances"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.683401","article-title":"Inflammatory pathophysiology as a contributor to myeloproliferative neoplasms","volume":"12","author":"Fisher","year":"2021","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international chapel hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheumatism"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202521056","article-title":"Exploring the vasculitis-tumors link: epidemiological patterns, mechanistic insights, and clinical implications","author":"Shi","year":"2026","journal-title":"Advanced Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.587089","article-title":"Cellular signaling pathways in medium and large vessel vasculitis","volume":"11","author":"Watanabe","year":"2020","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab505","article-title":"Neutrophil extracellular traps in giant cell arteritis biopsies: presentation, localization and co-expression with inflammatory cytokines","volume":"61","author":"Palamidas","year":"2022","journal-title":"Rheumatology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004061","article-title":"Increased levels of NETosis in myeloproliferative neoplasms are not linked to thrombotic events","volume":"5","author":"Schmidt","year":"2021","journal-title":"Blood Advances"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2023.08.028","article-title":"Platelets and neutrophils cooperate to induce increased neutrophil extracellular trap formation in JAK2V617F myeloproliferative neoplasms","volume":"22","author":"Guy","year":"2024","journal-title":"J Thromb Haemostasis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan8292","article-title":"Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms","volume":"10","author":"Wolach","year":"2018","journal-title":"Sci Transl Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41392-024-01933-x","article-title":"Neutrophil extracellular traps in homeostasis and disease","volume":"9","author":"Wang","year":"2024","journal-title":"Sig Transduct Target Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.118.313283","article-title":"Macrophage inflammation, erythrophagocytosis, and accelerated atherosclerosis in jak2 V617F mice","volume":"123","author":"Wang","year":"2018","journal-title":"Circ Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.589048","article-title":"JAK2V617F mutation promoted IL-6 production and glycolysis via mediating PKM1 stabilization in macrophages","volume":"11","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003432","article-title":"Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study","volume":"17","author":"Pujades-Rodriguez","year":"2020","journal-title":"PloS Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413449","article-title":"A phase 3 trial of upadacitinib for giant-cell arteritis","volume":"392","author":"Blockmans","year":"2025","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3012-z","article-title":"Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib","volume":"77","author":"Bryan","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024362","article-title":"Ruxolitinib targets JAK-STAT signaling to modulate neutrophil activation in refractory macrophage activation syndrome","volume":"146","author":"Ma","year":"2025","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1197342","article-title":"Changes in the molecular profiles of large-vessel vasculitis treated with biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors","volume":"14","author":"Matsumoto","year":"2023","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.881705","article-title":"Perspectives of JAK inhibitors for large vessel vasculitis","volume":"13","author":"Watanabe","year":"2022","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.12890\/2025_005615","article-title":"Leukocytoclastic vasculitis in JAK2-positive essential thrombocythemia: a case of cytokine-driven urticarial rash responsive to ruxolitinib","volume":"12","author":"Aldarayseh","year":"2025","journal-title":"Eur J Case Rep Intern Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025018011","article-title":"Towards new therapy endpoints in polycythemia vera: targeting clonal and inflammatory pathways","volume":"10","author":"Barbui","year":"2026","journal-title":"Blood Adv"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1781998\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T05:26:06Z","timestamp":1773379566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1781998\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2026.1781998"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1781998","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"article-number":"1781998"}}